Mallinckrodt‘s (NYSE: MNK) Stratatech has won an additional $26 million in Project BioShield funding from the the U.S. Biomedical Advanced Research and Development Authority to support pediatric studies of its StrataGraft engineered skin tissue.
The funding will support continued development of the StrataGraft as a potential medical countermeasure for large-scale burn incidents, U.K.-based Mallinckrodt said. BARDA previously supplied funding to Stratatech during its Phase 3 trial of the Stratagraft in adults, which explored the safety and efficacy of the device in promoting autologous skin regeneration of complex skin defects in partial-thickness burns.
With the $26 million, Stratatech said it has received approximately $86 million, and has the potential to receive an additional $74 million for the project.
“We are very pleased that BARDA has continued to see the potential benefit StrataGraft can bring as a much-needed therapeutic option for patients – both adults and children – with high unmet medical need. This is particularly important in the event of tragic mass burn incidents. The expanded partnership with BARDA to assess StrataGraft’s efficacy and safety in the vulnerable pediatric population is aligned with Mallinckrodt’s focus on improving outcomes for patients with severe and critical conditions in particularly vulnerable populations,” Mallinckrodt chief scientific officer Dr. Steven Romano said in a press release.